Global C-reactive Protein Testing Market Growth Report 2024-2032
Global C-reactive Protein Testing Market Share, Growth Report 2024-2032

C-Reactive Protein Testing Market Share, Size, Trends, Industry Analysis Report, By Assay Type (Immuno-turbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others); By Detection Range; By Disease Area; By End-Use; By Region; Segment Forecast, 2023 - 2032

  • Published Date:Feb-2024
  • Pages: 118
  • Format: PDF
  • Report ID: PM1770
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

The global C-reactive protein testing market was valued at USD 1,834.23 million in 2023 and is expected to grow at a CAGR of 2.7% during the forecast period.

The C-reactive protein (CRP) test calculates the level of CRP in the blood, indicating inflammation and can be associated with various infections and medical conditions. This test is particularly useful in assessing the risk of developing cardiovascular disorders, including coronary artery disease, which can prime to a major heart attack. The market demand for CRP testing is expected to increase due to the rising prevalence of cardiovascular diseases and the adoption of point-of-care devices.

Elevated levels of CRP in the plasma can indicate inflammation, which may be caused by a wide range of diseases, including inflammatory and malignant conditions. High readings of CRP testing can also indicate inflammation in the heart or blood vessels, thereby increasing the risk of heart disease.

C-reactive Protein Testing Market Size

To Understand More About this Research: Request a Free Sample Report

Furthermore, the COVID-19 pandemic has positively impacted the growth of the CRP testing market. Due to increased demand for the test, the adoption of CRP testing has proven beneficial in the early detection and assessment of disease severity during COVID-19. This trend is expected to continue and drive market growth in the foreseeable future.

Plasmonic nanoparticles (PNPs) possess versatile optical properties, making them valuable tools for biosensing applications. A research study conducted by BabeTM-Bolyai University in Romania and published in July 2021 provided an overview of assays based on plasmonic nanoparticles for detecting C-reactive protein (CRP). The study also demonstrated using recently developed point-of-care assays for fast CRP testing. These advancements are expected to contribute to the accelerated growth of the C-reactive protein testing market.

C-reactive protein is considered a marker for evaluating the severity of infections and monitoring therapeutic progress, per the guidance provided by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). In addition, Chinese guidelines recommend using CRP tests, along with additional clinical parameters, for evaluating and following up on SARS-CoV-2 disorder. Organizations like Aidian and Abbott offer products that serve as supportive diagnostic tools in managing COVID-19 infections.

For example, Aidian provides user-friendly QuikRead go CRP tests and a portable QuikRead go instrument for quantitatively measuring CRP. Also, Abbott provides the Afinion CRP and Afinion 2 Analyzer test, which provides results in just 3 minutes. The increased demand for CRP testing in research and clinical settings, driven by the COVID-19 pandemic, is expected to impact market growth positively.

C-Reactive Protein Testing

Industry Dynamics

  • Growth Drivers
  • Rising Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases is projected to drive the industry's demand for c-reactive protein (CRP) testing. Detection of high levels of CRP is often associated with cardiovascular diseases. According to the World Health Organization (WHO), in 2019, around 17.9 million individuals expired from cardiovascular disorders, accounting for 32% of global deaths. Most (85%) of these fatalities were attributed to heart attacks or strokes.

Moreover, there is a growing focus on implementing point-of-care screening and innovative techniques for CRP testing, supported by government initiatives. These initiatives aim to enhance accessibility and convenience in diagnosing and monitoring cardiovascular diseases. The development of advanced techniques in CRP testing is expected further to drive the growth of the CRP testing market.

C-reactive protein (CRP) tests diagnose inflammatory disorders like endometriosis, inflammatory bowel disease, rheumatoid arthritis, cancer, lupus, and cardiovascular disease. Elevated CRP, along with risk factors like high blood pressure, hypertension, high cholesterol, and diabetes, indicates significant heart disease risk. Early identification reduces heart attack and stroke risks. CRP aids in discovering medicines for inflammatory diseases in vitro and in vivo, contributing to market growth.

Report Segmentation

The market is primarily segmented based on assay type, detection range, disease area, end-use, and region.

By Assay Type

By Detection Range

By Disease Area

By End-Use

By Region

  • Immuno-turbidimetric Assay
  • Clinical
  • Non-clinical
  • Chemiluminescence Immunoassay
  • Others
  • hs (high sensitivity) CRP
  • Conventional CRP
  • cCRP
  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others
  • Clinics
  • Hospitals
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Home Care Settings
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Assay Type Analysis

  • The immunoturbidimetric assays segment accounted for the largest revenue share in 2023

The immunoturbidimetric assays segment accounted for the largest revenue share in 2023. The application of this technique in chronic diseases of the respiratory and cardiac systems will contribute to its dominance. Advancements in the Chemiluminescence Immunoassay (CLIA) process, providing accurate results, will further drive growth in this segment.

Technological advancements in immunoturbidimetric assays will fuel market growth. Researchers worldwide are developing advanced and innovative assays to support rapid and precise CRP testing. For example, an examination publicized in January 2021 by investigators from D.M. Vasudevan Agappe Diagnostic Limited, India, established using a latex-enhanced immunoturbidimetric assay for highly sensitive and wide-range CRP detection in human serum.

By Detection Range Analysis

  • The hs (high sensitivity) CRP segment expected to witness the fastest market share during the forecast period.

The high-sensitivity C-reactive protein (hs-CRP) testing segment expected to witness the fastest market share during the forecast period, driven by advancements in CRP technologies. Compared to traditional CRP tests, hs-CRP testing is highly sensitive and can detect even small increases in CRP levels in the human body. It makes it valuable in identifying the risk for coronary artery disease, contributing to the demand for this segment.

Moreover, the market is witnessing the development of various hs-CRP-based point-of-care (POC) testing devices by different market entities, further boosting the market growth. Technical improvements in conventional CRP methods are also expected to drive the development of the hs-CRP testing segment. Introducing nano-bio hybrid materials in CRP biosensors has appeared as an advantageous procedure for rapid and accurate CRP measurement using portable biosensors. In a study published in May 2021, researchers from Korea outlined the advances in spectroscopy-based, electrical CRP biosensors and electrochemical, comprised of nanomaterial hybrids and biomaterial. Such analyses are expected to boost the adoption of advanced CRP tools by end users, fostering the growth of the hs-CRP testing market.

C-Reactive Protein Testing Seg

North America accounted for the largest market share in 2023

In 2023, North America accounted for the largest market share, primarily driven by the high prevalence of cardiovascular diseases in countries like the U.S. and Canada. For instance, in 2019, the U.S. witnessed over 356,000 out-of-hospital cardiac arrests (OHCA) annually, with a significant fatality rate of over 90%. It, coupled with advanced healthcare facilities and government initiatives, is expected to propel the growth of the c-reactive protein testing market in the region.  

Asia Pacific is anticipated to exhibit fastest growth during the forecast period, fueled by a continuously increasing population and a rising senior population in countries like Japan and China. The region is also experiencing healthy adoption of CRP testing in hospitals and a growing prevalence of malaria and cardiovascular diseases. These factors are anticipated to boost the market's growth in Asia Pacific in the coming years.

C-Reactive Protein Testing Reg

Key Market Players & Competitive Insight

The C-reactive protein (CRP) Testing Market is characterized by intense competition among key players striving to offer innovative solutions and maintain a significant market share. As a vital component in assessing inflammation and associated health risks, CRP testing has garnered attention from various healthcare organizations and diagnostic companies. This competitive landscape is shaped by factors such as technological advancements, product differentiation, strategic collaborations, and a focus on research and development.

Some of the companies working in the global CRP market include:

  • Abaxis, Inc.
  • Abbott, Danaher
  • Aidian
  • F. Getein Biotech, Inc.
  • Hoffmann-La Roche Ltd.
  • HORIBA, Ltd., Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Ortho Clinical Diagnostics
  • Quest Diagnostics
  • Randox Laboratories Ltd.
  • Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
  • Zoetis

Recent Developments

  • In November 2020, a study conducted by U.S. researchers supported the use of daily C-reactive protein (CRP) values in hospitalized COVID-19 patients.
  • In May 2020, ProciseDx submitted a 510k application for the company CRP test. This test utilizes ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care tools, commonly used as an inflammatory marker in gastrointestinal therapy.

C-Reactive Protein Testing Market Report Scope

Report Attributes


Market size value in 2024

USD 1,879.35 million

Revenue forecast in 2032

USD 2,331.22 million


2.7% from 2024 – 2032  

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

By Assay Type, By Detection Range, By Disease Area, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation.



C-Reactive Protein Testing Market Size Worth $ 2,331.22 Million By 2032

The global key market players include Randox Laboratories Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics, Aidian, Abaxis.

North America is contribute notably towards the C-reactive Protein Testing Market.

C-reactive Protein Testing Market is expected to grow at a CAGR of 2.7% during the forecast period.

C-reactive Protein Testing Market report covering key segments are assay type, detection range, disease area, end-use, and region.